(±)-trans-ACPD

Confirm delete?

(±)-trans-ACPD

Zoom

Cat No: 28849

Biochemicals - Receptor Pharmacology

(±)-trans-ACPD is an agonist of metabotropic glutamate receptors (mGluRs; EC50s = 15, 2, 40, 23, and 82 µM for mGluR1, -2, -3, -5, and -6, respectively, in CHO cells expressing recombinant receptors).{47711} It also activates mGluR4 in baby hamster ki...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

(1R,3S)-1-aminocyclopentane-1,3-dicarboxylic acid

Correlated keywords:

39026-63-6 39026-64-7 56827-69-1 207729-09-7 m GluR mGlu R AC PD mGluR2 mGluR3 mGluR5 mGluR6 AMP LY 233053 274614

Product Overview:
(±)-trans-ACPD is an agonist of metabotropic glutamate receptors (mGluRs; EC50s = 15, 2, 40, 23, and 82 µM for mGluR1, -2, -3, -5, and -6, respectively, in CHO cells expressing recombinant receptors).{47711} It also activates mGluR4 in baby hamster kidney cells with an EC50 value of approximately 800 µM. (±)-trans-ACPD increases cAMP accumulation in adult rat cerebral cortex slices (EC50 = 47.8 µM) but not in isolated rat embryonic neurons or neonatal glial cells when used at concentrations ranging from 1 to 1,000 µM.{47712} (±)-trans-ACPD (10-1,000 µM) increases phosphoinositide hydrolysis in neonatal rat cerebral cortex and hippocampal slices. It induces clonic convulsions in neonatal rats (ED50 = 100 mg/kg), an effect that can be reversed by administration of the NMDA receptor antagonists LY233053 and LY274614.{47713}

Size	1 mg
Shipping	dry ice
CAS Number	67684-64-4
Molecular Formula	C₇H₁₁NO₄
SMILES	OC([C@H]1CC[C@@](C(O)=O)(N)C1)=O
Molecular Weight	173,2
Formulation	A crystalline solid
Purity	≥95%
Custom Code	2918.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.